Media OutReach
BeOne Medicines Honored with the Global Oncology Innovation Leadership Award at BIOHK 2025, Supporting “1+” to Accelerate the Delivery of Innovative Cancer Therapies
Ms. Yiya Chen, General Manager (Taiwan, Hong Kong & Macau) of BeOne, stated, “Receiving the Global Oncology Innovation Leadership Award not only affirms BeOne’s R&D capabilities, but also motivates us to accelerate the transformation of innovative breakthroughs into tangible benefits for patients in the Greater Bay Area, including Hong Kong. Currently, we offer three novel cancer therapies in Hong Kong, covering BTK inhibitor, PD-1 inhibitor, and IL-6 inhibitor. Moving forward, we will proactively leverage the opportunities under the “1+” mechanism to expedite the importation of more international-standard compliant, self-developed medicines, enabling rapid, extensive access to effective treatment for local cancer patients.
Global Research & Development Together with Powered Innovation
Since its establishment in 2010, BeOne has been upholding its mission of “Cancer has no borders. Neither do we,” focusing on developing high-quality, self-developed medicines that meet international standards, with a commitment to accessibility and affordability of innovative cancer treatments. To date, BeOne has conducted over 170 clinical trials across 45 countries and regions, building one of the world’s largest oncology research teams. More than 1.8 million patients have benefited from the achievements of its research and development.
- BTK inhibitor: BeOne’s first independently developed innovative drug, and the only treatment worldwide in its class to have completed head-to-head clinical trials in both Chronic Lymphocytic Leukemia (CLL) and Waldenström’s Macroglobulinemia (WM)1. It has been approved in more than 75 markets and was honored with the prestigious Prix Galien Suisse in 20232..
- PD-1 inhibitor (immunotherapy): Approved in Hong Kong for six indications, including non-small cell lung cancer, esophageal cancer, and gastric cancer, with expansion to nasopharyngeal carcinoma and lung cancer — two of the most prevalent cancer types in Asia. This therapy is marketed in 47 countries and regions including the United States, European Union, China, and Japan, with over 60 indication-approval applications submitted to expand its global coverage.
BeOne’s integrated development approach combines robust R&D capabilities, a PoC-driven strategy and a wide portfolio of assets. With over 40 Phase 3-ready or registration-potential clinical trials and more than 40 R&D assets in clinical and commercialization stages, BeOne maintains leadership across multiple technology platforms, including multi-specific antibodies, chimeric degradation activating compounds (CDACs), and antibody-drug conjugates (ADCs).
Through the PoC strategy, BeOne concentrates on highly differentiated and promising molecule candidates. The company has successfully pushed through the clinical development for 20 drug molecules and obtained regulatory approvals across six continents, demonstrating its outstanding R&D efficiency and globalization strategy.
Globalization to Strengthen Sustainable Supply
BeOne has established three major R&D and manufacturing bases in the United States and China, encompassing the entire industry chain from research and development to manufacturing and commercialization. Notably, the Guangzhou campus spans 1.3 million ft2 and features advanced manufacturing capabilities to produce large-molecule drugs, serving as a core supply hub in the Greater Bay Area, including Hong Kong. This footprint ensures a stable drug supply and enhances accessibility for patients in the region.
As one of the world’s top 20 leading oncology patent holders3 and listed as one of the “World’s Top 10 Most Inventive Pharmaceutical Companies”4 by IDEA Pharma in 2025, BeOne will continue to devote its efforts to researching hematologic and solid tumors. Leveraging Hong Kong as a strategic bridge between Asia and the international community, BeOne is committed to accelerating the development and delivery of innovative therapies, collaboratively driving a new paradigm for cancer care regionally and globally.
Prof. Albert Yu, Chairman of Hong Kong Biotechnology Organization, remarked, “BeOne’s leadership in oncology is fully evident in its innovative drug development, globalization strategy, and significant improvements in quality of life for cancer patients locally and worldwide. Grounded in rigorous scientific research, BeOne aligns clinical needs with accessibility considerations across various markets to launch multiple self-developed innovative medicines to the global stage. The company’s efforts represent scientific excellence and a profound commitment to cancer patients, deserving of the Global Oncology Leadership Award.”
This press release contains forward-looking statements, and actual results may differ from those expressed or implied in these statements. All information provided herein is as of the date of this release, and unless required by law, BeOne has no obligation to update or revise any such information.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential benefits of sonrotoclax; BeOne’s expectations regarding sonrotoclax’s clinical development, regulatory milestones, submissions and approvals; BeOne’s plans to present the full data at an upcoming medical meeting; and BeOne’s plans, commitments, aspirations and goals under the caption “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.
[3] Top 50 Pharma: Oncology patent leaders 2024, Drug Discovery & Development
[4] 2025 Pharmaceutical Innovation and Invention Index, IDEA Pharma
Hashtag: #BeOneMedicines
The issuer is solely responsible for the content of this announcement.
About BeOne Medicines
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.
To learn more about BeOne, please visit 
www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.
About BIOHK Hong Kong International Biotechnology Conference & Exhibition
BIOHK Hong Kong International Biotechnology Conference & Exhibition is Asia’s premier biotechnology conference and exhibition. It aims to create a collaborative platform for industry leaders, innovators, and stakeholders to come together and drive the development of biotechnology. BIOHK is dedicated to advancing the biotech sector by not only providing a stage to showcase technological innovations but also offering a launchpad for companies seeking a market expansion to the Greater Bay Area and Mainland China. By combining educational seminars, strategic partnership opportunities, and governmental support, BIOHK empowers participants to foster significant advancements with profound impacts on global health and technology.
Media OutReach
TELOSIN Introduces “The Dual Transformation,” Pairing Y PRO Red and Y PRO Blue with the New Lumiactive Collection
The new skincare system brings together FDA-cleared, NASA-inspired light technology, complementary formulations and award-winning patented design by Karim Rashid, following a Hong Kong launch attended by more than 2,000 guests
HONG KONG SAR – Media OutReach Newswire – 21 July 2026 – TELOSIN has introduced “The Dual Transformation,” a new approach to personalised at-home skincare built around two dedicated light-based beauty devices—the Y PRO Red and Y PRO Blue—and the complementary Lumiactive Collection.
The launch brings together advanced light-based technology, targeted skincare formulations and award-winning patented design created in collaboration with internationally acclaimed designer Karim Rashid.
Rather than incorporating multiple generalised modes within a single device, TELOSIN developed two distinct devices and two dedicated skincare pathways.
Y PRO Red is designed for a rejuvenation-focused skincare routine, supporting the appearance of firmness, texture and radiance.
Y PRO Blue is designed for routines focused on blemish-prone, oily or visibly unsettled skin.
The devices combine FDA-cleared technology with light-based innovation inspired by scientific developments associated with NASA research.
Introducing the Lumiactive Collection
The Y PRO devices are accompanied by the new Lumiactive Collection, comprising:
- LUMIRED Red LED Treatment Gel
- LUMIBLUE Blue LED Treatment Gel
- Blue Light Defense Cream
Together, the devices and complementary formulations establish TELOSIN’s connected Prepare, Treat, Protect approach to skincare.
The dedicated Lumiactive treatment gels are designed to prepare the skin for the corresponding Y PRO routine, while Blue Light Defense Cream completes the ritual as part of the brand’s wider daily skincare approach.
By developing the devices and formulations as one connected collection, TELOSIN aims to make advanced light-based skincare easier to understand, personalise and incorporate into regular at-home routines.
The result is a complete ecosystem built around two targeted transformations: a red-light pathway focused on rejuvenation and a blue-light pathway focused on skin clarity and balance.
Scientific Insight Behind TELOSIN
TELOSIN has expanded the scientific conversation surrounding the launch through its expert video series, “The Science Behind Telosin,” available on the brand’s website.
The series features expert perspectives from two medical professionals:
Dr. Omer Wolf, MD, a specialist in plastic and reconstructive surgery and advanced facial aesthetic procedures.
Dr. Uri Berger, MD, a specialist in aesthetic medicine with extensive international medical training and experience.
Through the expert series, TELOSIN provides consumers with accessible information about the principles behind light-based skincare and the evolving relationship between professional aesthetic knowledge, beauty technology and at-home routines.
The inclusion of medical perspectives within the wider educational programme reflects TELOSIN’s commitment to supporting product innovation through informed scientific discussion and responsible consumer education.
Award-Winning Patented Design by Karim Rashid
The Y PRO Red and Y PRO Blue were created in collaboration with Karim Rashid, one of the world’s most recognised contemporary designers.
The devices feature award-winning patented design that combines Rashid’s distinctive visual language with TELOSIN’s advanced beauty technology.
Their fluid silhouettes, individual colour identities and ergonomic forms were developed not simply to contain sophisticated technology, but to transform the devices into desirable contemporary objects that can become a natural part of the user’s daily beauty environment.
The collaboration reflects TELOSIN’s belief that advanced skincare devices should deliver a sophisticated combination of performance, simplicity, comfort and emotional connection.
“The Dual Transformation” Unveiled to More Than 2,000 Guests in Hong Kong
The complete collection was officially presented on 30 June 2026 through “The Dual Transformation,” an immersive launch experience held at WTC Mall in Hong Kong.
The large-scale event welcomed more than 2,000 guests, including consumers, members of the Hong Kong media, influencers, beauty industry professionals and invited partners.
The launch featured internationally acclaimed designer Karim Rashid, MIRROR member Ian Chan, celebrated actress and singer Linda Chung, and Dr. Harvey Ho.
Karim Rashid introduced the creative thinking behind the award-winning patented design of the devices, while Dr. Harvey Ho discussed the different applications and skincare pathways associated with red and blue light technology.
Ian Chan and Linda Chung joined the launch presentation to experience the two routines and demonstrate how the Y PRO devices and complementary Lumiactive formulations can be incorporated into contemporary at-home skincare.
“The Dual Transformation demonstrates that advanced beauty technology does not need to feel clinical or complicated,” said Dr. Harvey Ho.
“By bringing together two dedicated light-based devices with complementary Lumiactive formulations, TELOSIN has created a more focused and intuitive approach to at-home skincare. The distinction between the red and blue light pathways also helps consumers better understand how different technologies can support different skincare needs.”
With more than 2,000 guests attending, the event marked a major public introduction of TELOSIN’s broader product ecosystem: two targeted devices, three complementary skincare formulations and one connected approach to personalised light-based skincare.
A Complete Dual Skincare System
With Y PRO Red, Y PRO Blue and the Lumiactive Collection, TELOSIN is introducing more than two individual beauty devices.
“The Dual Transformation” represents a complete skincare system built around clearly defined objectives, dedicated formulations and award-winning patented design.
It reflects the brand’s wider ambition to make sophisticated light-based technology more personalised, intuitive and accessible, while maintaining the premium design experience expected by contemporary beauty consumers.
Hashtag: #TELOSIN
https://www.telosin.com
https://www.instagram.com/telosin_official/?hl=en
The issuer is solely responsible for the content of this announcement.
About TELOSIN
TELOSIN develops premium at-home skincare devices and complementary formulations that bring together advanced light-based technology, scientific insight, award-winning patented design and an intuitive user experience.
Through continued product development and collaborations with internationally recognised designers and medical professionals, TELOSIN aims to make sophisticated beauty technology more personalised, accessible and desirable.
TELOSIN products are available online atwww.telosin.com, at The Mineral Boutique stores, through selected premium retailers and at leading clinics.
For further information, expert videos and product details, visitwww.telosin.com.
Media OutReach
SearchInform: A Risky Game – How FIFA World Cup 2026 Led to Mass Corporate Data Leaks
Experts claim that corporate employees in Southeast Asia are neglecting cybersecurity rules due to their love for football, leading to an increase in fraud cases.
SINGAPORE – Media OutReach Newswire – 21 July 2026 – Although the tournament itself took place in North America, Asia’s massive football fan base created the perfect conditions for data leaks.
Fraudsters are capitalizing on football fans by creating fake streaming platforms and malicious Android applications that steal saved passwords and account credentials directly from browsers. Criminals are also setting up fraudulent websites, as well as sending phishing emails to company employees disguised as gifts, promotions, and office betting pools.
“During major global events, the corporate security perimeter is under huge stress,” said Francis Yeoh, Country Director at SearchInform Malaysia. “Employees access streaming websites from corporate devices to watch matches live. Traditional network-edge security is insufficient—the real danger comes from the employee side of the fence. Employees could watch a translation on a malware-infested website, they could download streaming applications with hidden malware, or use corporate credentials to register for fraudulent giveaways.”
According to Group-IB and the FBI, from August 2025 to June 2026, more than 4,300 fake websites were registered fully mimicking FIFA interfaces, ticketing systems, streaming platforms, and World Cup employment portals.
How Organizations Can Reduce Cyber Risks During Football Season
- Monitor the use of corporate devices. Remind employees that corporate workstations should not be used for personal purposes, including streaming, downloading unofficial apps, or visiting suspicious websites. This measure alone can help reduce exposure to many malware threats.
- Strengthen password security. Monitor risky password practices, as some employees may reuse corporate credentials for personal services. If one of these services is compromised, corporate accounts and systems may be put at risk as well.
- Enforce multi-factor authentication. Apply MFA for privileged employees on a regular basis and temporarily strengthen authentication requirements for remote employees during high-risk periods. This provides an additional layer of protection against unauthorized access.
- Monitor data access patterns. Track who accesses critical information, from where, and monitor its transmission to prevent data loss. Make sure protection also covers cloud services, as corporate data is no longer limited to on-premises storage.
Hashtag: #SearchInform #Cybersecurity, #FIFA2026, #DataProtection
The issuer is solely responsible for the content of this announcement.
About SearchInform
SearchInform is an information security and risk management product vendor as well as an MSS provider. The company’s clients are more than 4000 companies in 20+ countries. Today, the team has products and services for comprehensive protection against insider threats at all levels of corporate information systems: FileAuditor (the DCAP class solution); DLP system with extended functionality; Risk Monitor (advanced AI-powered platform for internal threat mitigation); SIEM system, Information Security outsourcing service.
More than 500 international buyers from 55 economies have confirmed participation
KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 21 July 2026 – The Malaysia External Trade Development Corporation (MATRADE) invites Malaysian companies to seize new global business opportunities by registering for its flagship International Sourcing Programme (INSP) at the upcoming 22nd Malaysia International Halal Showcase (MIHAS) at MITEC, Kuala Lumpur from 23 to 26 September 2026.
Building on the strong momentum of INSP MIHAS 2025, which generated RM3.63 billion in sales, this year’s edition is seeing strong international buyer interest, reinforcing MIHAS’ position as a leading global halal trade platform. INSP MIHAS 2026 features key products and services categories including:
- Agricultural Produce;
- Apparel, Garments and Accessories;
- Beverages;
- Education;
- Fashion Accessories and Textiles;
- Footwear;
- Franchise;
- Gifts, Souvenirs and Jewellery;
- Gloves;
- Islamic Financial Services;
- Information and Communication Technology;
- Logistics;
- Machinery and Equipment;
- Packaging and Containers;
- Palm Oil Products;
- Pet Products;
- Pharmaceuticals;
- Toiletries and Cosmetics; and
- Prepared Food.
Beyond the conventional halal food and beverage segment, this year’s edition is also seeing growing interest in services sectors.
INSP MIHAS connects pre-qualified international buyers with Malaysian halal product and service exporters through pre-arranged one-on-one business meetings across key halal sectors. As buyer meeting slots are limited and allocated through a structured matching process, Malaysian companies are strongly encouraged to register early via the online portal.
According to MATRADE’s Chief Executive Officer (CEO), Mr. Abu Bakar Yusof, “Since the inception of MIHAS in 2004, the International Sourcing Programme (INSP) has generated over RM20.62 billion in export sales for Malaysian companies, with the participation of nearly 8,000 international buyers, benefiting 10,600 Malaysian sellers through 67,200 structured business meetings.
For this year, we are targeting the participation of approximately 300 buyers, of which 50 are premium buyers, reflecting our commitment to attracting high-quality decision-makers and creating greater business opportunities for Malaysian companies. We are also targeting RM2 billion in export sales under the INSP component for MIHAS 2026. To date, we have received interest from more than 500 international buyers across 55 economies, and we encourage Malaysian companies to register early to maximise their business matching opportunities.”
MIHAS 2026 is expected to generate total sales of RM4.50 billion, including export sales from the INSP. “As it stands, 15% of the interested buyers comprise returning buyers, demonstrating sustained confidence in Malaysian exporters and the compelling value proposition they continue to offer in global markets,” he added. This year’s INSP has attracted buyers from 55 different economies.
Malaysian exporters can register through the INSP MIHAS online portal and MADANI Digital Trade Platform (MDTP) before 31st July 2026 and take advantage of one of MIHAS’ most impactful business matching initiatives.
Hashtag: #MIHAS2026
The issuer is solely responsible for the content of this announcement.
Malaysia External Trade Development Corporation (MATRADE)
For more information, please contact:
Aninawati Saleh
Head of Corporate Communication
Malaysia External Trade Development Corporation (MATRADE)
Tel (Direct) : 03 – 6207 7077 (7826)
Email : co***********@*********ov.my
About Malaysia International Halal Showcase (MIHAS) 2026
Since it began in 2004, the Malaysia International Halal Showcase (MIHAS) has grown into a major platform for Halal trade and has helped strengthen the global industry’s position in Halal standards, governance, and market access. Recognised as a Guinness World Records holder and hosted by the Ministry of Investment, Trade and Industry (MITI) with the Malaysia External Trade Development Corporation (MATRADE) as organiser, MIHAS now covers 14 sectors, from food and beverages and pharmaceuticals to Islamic finance, modest fashion, personal care, technology, services, and Muslim-friendly tourism. The 22nd edition of MIHAS, themed “Shaping Trust, Driving Resilience”, will focus on regulated-by-design governance and technology-enabled trade.
About MATRADE
The Malaysia External Trade Development Corporation (MATRADE) was established on 1 March 1993 as the national trade promotional arm under Malaysia’s Ministry of Investment, Trade and Industry (MITI).
MATRADE’s primary role is to assist Malaysian exporters in developing and expanding their export markets. Aligned with Malaysia’s commercial diplomacy efforts, MATRADE is the nation’s trade facilitator and champion of Malaysian-made products and services on the global stage.
